The Zach System factory, based in Avrillé, will benefit from a public investment of 48.7 million euros to strengthen or relocate the production of essential medicines in France.
The Zach System factory will benefit from a new investment. – Google Street View
As part of the France 2030 plan, the Zach System factory, located in Avrillé in Maine-et-Loire, was designated as one of seven beneficiaries of public support aimed at relocalizing the production of essential medicines in France .
The State announced aid of 48.7 million euros for this site, specializing in fine chemicals and the production of active pharmaceutical ingredients. This aid is in addition to the 86 million euros of investments announced in May 2024 during the seventh edition of Choose France.
Relocation for health and strategic issues
The Covid-19 crisis has highlighted the flaws in global supply chains, particularly in the healthcare sector. “ Today, between 60 and 80% of active pharmaceutical ingredients used in Europe come from countries such as China and India », Specifies the Ministry of Health.
Zach System, a subsidiary of the Italian pharmaceutical group Zambon, has been based in Avrillé since 1972. The factory produces a wide range of molecules, including antivirals, anticancers and antidiabetics.
Thanks to these new investments, the company plans to construct four additional buildings, including a 1,500 m² production workshop, which should be operational at the end of 2025. This workshop will introduce continuous production technology, aimed at optimizing production capacities. manufacturing, replacing traditional batch processes.
In addition to technical developments, the subsidiary also plans to create around 100 jobs. These recruitments will strengthen the 230 employees currently employed on the site.
Total funding of 120 million euros
Zach System is just one of seven projects supported in this phase of France 2030, which provides total public funding of 120 million euros for this new wave of investments. These projects are in addition to those already selected in 2023 and other initiatives of the France Relance plan. In total, 42 essential medicines were identified as priorities for relocated production.
« The relocation of essential medicines represents a dual sovereignty issue, both industrial and health. Public support is essential to provide French manufacturers with the means to compete with their non-European competitors », Explains the General Directorate of Enterprises.
Among the six other new projects announced as part of France 2030, we find the Ipsophene factory in Toulouse (31), the Delpharm sites in Lys-lez-Lannoy (59) and Chambray-Lès-Tours (37), Adhex Pharma in Chenôve (21), Benta Lyon in Saint-Genis-Laval (69), as well as NextPharma in Limay (78).
Follow all the news from Angers on the Angers Villactu WhatsApp channel.
